AR057887A1 - Composiciones y metodos de tratamiento de trastornos del snc - Google Patents

Composiciones y metodos de tratamiento de trastornos del snc

Info

Publication number
AR057887A1
AR057887A1 ARP060104925A ARP060104925A AR057887A1 AR 057887 A1 AR057887 A1 AR 057887A1 AR P060104925 A ARP060104925 A AR P060104925A AR P060104925 A ARP060104925 A AR P060104925A AR 057887 A1 AR057887 A1 AR 057887A1
Authority
AR
Argentina
Prior art keywords
substituted
unsubstituted
compound
treatment
branched
Prior art date
Application number
ARP060104925A
Other languages
English (en)
Inventor
Laurence Wu
Oren M Becker
Mercedes Lobera
Boaz Inbal
Dale S Dhanoa
Silvia Noiman
Yael Marantz
Dongli Chen
Alexander He
Original Assignee
Mohanty Pradyumna
Epix Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mohanty Pradyumna, Epix Pharm Inc filed Critical Mohanty Pradyumna
Publication of AR057887A1 publication Critical patent/AR057887A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicacion 1: Una composicion farmacéutica, caractetizada porque comprende - un primer compuesto que tiene la siguiente formula (1) en donde R1 puede ser alquilo (C1-8), ramificado o no ramificado; un anillo carbocíclico (C1-8) sustituido o no sustituido; haloalquilo ramificado o no ramificado, un anillo arilo o heteroarilo sustituido o no sustituido o un anillo (CH2)p-arilo o (CH2)p-heteroarilo sustituido o no susittuido, donde p es 1, 2, 3 o 4; R2 y R3, tomados juntos, forman un anillo de piperidina; pirrolidina, azepán, aziridina o azetidina sustituido o no sustituido; y n es 1, 2, 3, 4, 5 o 6; y sales y/o ésteres aceptables para uso farmacéutico del mismo, donde el primer compuesto está presente en una cantidad tal que si se administrara sola no mejora sustancialmente la memoria; y - un segundo compuesto que es un inhibidor de colinesterasa o acetilcolinesterasa y está presente en una cantidad tal que si se administrara sola no mejora sustancialmente la memoria. Moduladores de tienopiridinona del receptor 5-HT4, y en particular el uso de estos compuestos y sus composiciones farmacéuticas, por ejemplo, en el tratamiento, la modulacion y/o la prevencion de las afecciones fisiologicas asociadas con la accion de serotonina, tal como en el tratamiento del mal de Alzheimer, trastornos cognitivos, depresion y ansiedad.
ARP060104925A 2005-11-10 2006-11-09 Composiciones y metodos de tratamiento de trastornos del snc AR057887A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/271,019 US7598265B2 (en) 2004-09-30 2005-11-10 Compositions and methods for treating CNS disorders

Publications (1)

Publication Number Publication Date
AR057887A1 true AR057887A1 (es) 2007-12-26

Family

ID=37946751

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104925A AR057887A1 (es) 2005-11-10 2006-11-09 Composiciones y metodos de tratamiento de trastornos del snc

Country Status (17)

Country Link
US (2) US7598265B2 (es)
EP (1) EP1959954A2 (es)
JP (1) JP2009515877A (es)
KR (1) KR20080067001A (es)
CN (1) CN101340908A (es)
AR (1) AR057887A1 (es)
AU (1) AU2006315854A1 (es)
BR (1) BRPI0618493A2 (es)
CA (1) CA2629312C (es)
CR (1) CR10062A (es)
EA (1) EA200801302A1 (es)
IL (1) IL191168A0 (es)
MA (1) MA30037B1 (es)
NO (1) NO20082679L (es)
TW (1) TW200735868A (es)
WO (1) WO2007058805A2 (es)
ZA (1) ZA200804951B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612078B2 (en) * 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
US20050222175A1 (en) * 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7488736B2 (en) * 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7576211B2 (en) * 2004-09-30 2009-08-18 Epix Delaware, Inc. Synthesis of thienopyridinone compounds and related intermediates
US7407966B2 (en) * 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7598265B2 (en) * 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
WO2006081332A1 (en) * 2005-01-25 2006-08-03 Epix Delaware, Inc. Substituted arylamine compounds and their use as 5-ht6 modulators
GB0526258D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
EP2445877B1 (en) * 2008-12-03 2014-07-23 Nanotherapeutics, Inc. Bicyclic compounds and methods of making and using same
RU2569056C2 (ru) * 2009-04-13 2015-11-20 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Соединения-агонисты рецептора 5-нт4 для лечения расстройств познавательной способности
US20230139125A1 (en) * 2021-02-04 2023-05-04 Richard Natrillo Dietary supplement for improving brain performance

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3069412A (en) 1958-08-15 1962-12-18 Fmc Corp N-aminoazetidine and preparation thereof
CA933923A (en) 1969-12-19 1973-09-18 Eichenberger Kurt Process for the manufacture of new thiopyranes
GB1570494A (en) 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
DE2925175A1 (de) 1979-06-22 1981-01-08 Basf Ag Verfahren zur herstellung von isatosaeureanhydriden
IT1203323B (it) 1987-02-02 1989-02-15 Hoechst Italia Spa Additivo fotoattivatore per composizioni polimeriche costituito dal sale metallico di una cera ossidata
US5236917A (en) 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
DE4008726A1 (de) 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
DE4023270A1 (de) * 1990-07-21 1992-02-06 Hoechst Ag Hydrophile mischpolymere sowie deren verwendung in der reprographie
US5155115A (en) 1991-03-12 1992-10-13 Kyowa Hakko Kogyo Co., Ltd. Thienopyridine derivatives
US5219864A (en) 1991-03-12 1993-06-15 Kyowa Hakko Kogyo Co., Ltd. Thienopyridine derivatives
US5227387A (en) 1991-09-03 1993-07-13 Dowelanco Quinoline nematicidal method
DE4138820A1 (de) 1991-11-26 1993-05-27 Basf Ag Chinolin-3-carbonsaeureamide, deren herstellung und verwendung
DE4208254A1 (de) 1992-03-14 1993-09-16 Hoechst Ag Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid
DE4227747A1 (de) 1992-08-21 1994-02-24 Basf Ag Heteroaromatisch kondensierte Hydroxypyridoncarbonsäureamide, deren Herstellung und Verwendung
US5409948A (en) 1992-11-23 1995-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating cognitive disorders with phenserine
JPH06239858A (ja) 1993-02-16 1994-08-30 Otsuka Pharmaceut Co Ltd 末梢血管拡張剤
GB9306460D0 (en) 1993-03-29 1993-05-19 Smithkline Beecham Plc Novel compounds
JPH07324087A (ja) * 1994-04-04 1995-12-12 Taisho Pharmaceut Co Ltd 複素環化合物
TW449600B (en) 1994-04-19 2001-08-11 Takeda Chemical Industries Ltd Condensed-ring thiophene derivatives, their production and use
JP3829879B2 (ja) 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
DE19636769A1 (de) 1996-09-10 1998-03-12 Basf Ag 3-Substituierte Pyrido [4',3':4,5]thieno[2,3-d]pyrimidin-Derivate, ihre Herstellung und Verwendung
US6979309B2 (en) * 1997-02-14 2005-12-27 Nxstage Medical Inc. Systems and methods for performing blood processing and/or fluid exchange procedures
DE19724980A1 (de) 1997-06-13 1998-12-17 Basf Ag 3-Substituierte 3,4-Dihydro-thieno[2,3-d]pyrimidin-Derivate, ihre Herstellung und Verwendung
JPH11130777A (ja) 1997-08-13 1999-05-18 Takeda Chem Ind Ltd チエノピリジン誘導体、その中間体およびそれらの製造法
DE69839887D1 (de) 1997-10-02 2008-09-25 Eisai R&D Man Co Ltd Kondensierte pyridinderivate
US6103903A (en) 1998-02-26 2000-08-15 Neurogen Corporation 4-(4-piperidylmethyhlamino) substituted heteroaryl fused pyridines: GABA brain receptor ligands
DE19815026A1 (de) 1998-04-03 1999-10-07 Hoechst Schering Agrevo Gmbh Substituierte Piperidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
WO1999051932A2 (en) * 1998-04-08 1999-10-14 Moshier Gary S Launched munition neutralization of buried mines
BR9911612A (pt) 1998-06-02 2001-02-06 Osi Pharm Inc Composições de pirrolo[2,3d]pirimidina e seus usos
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
AU5259100A (en) 1999-04-28 2000-11-10 Respiratorius Ab Medicament
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
EP1229025A4 (en) 1999-10-01 2003-04-09 Japan Energy Corp NEW QUINAZOLINE DERIVATIVES
EP1270568A1 (en) 2001-06-19 2003-01-02 Biofrontera Pharmaceuticals AG 1-methyl-4-(3-ethoxy-9h-thioxanthene-ylidene)-piperidine and its use as 5-HT2B and/or H1 antagonist
WO2003020728A1 (en) 2001-08-30 2003-03-13 Pharmacia & Upjohn Company 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS
MXPA03000145A (es) 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
WO2004030629A2 (en) 2002-10-01 2004-04-15 Predix Pharmaceuticals Novel neurokinin antagonists and methods of use thereof
US7153858B2 (en) 2003-01-31 2006-12-26 Epix Delaware, Inc. Arylpiperazinyl compounds
US20050222175A1 (en) 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7612078B2 (en) 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
AU2004227913B2 (en) 2003-03-31 2010-12-02 Trovis Pharmaceuticals, Llc New piperidinylamino-thieno(2,3-d) pyrimidine compounds
US7119205B2 (en) 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
ES2293287T3 (es) 2003-07-25 2008-03-16 F. Hoffmann-La Roche Ag Combinacion de antagonista de mglur2 y de inhibidor de ache para el tratamiento de trastornos neurologicos agudos y/o cronicos.
GB0322140D0 (en) 2003-09-22 2003-10-22 Pfizer Ltd Combinations
EP1680120A2 (en) 2003-11-03 2006-07-19 Probiodrug AG Combinations useful for the treatment of neuronal disorders
US7488736B2 (en) * 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US20060084806A1 (en) 2004-07-21 2006-04-20 Ramasubramanian Sridharan Processes for the preparation of imidazo[1,2-a] pyridine derivatives
US7576211B2 (en) 2004-09-30 2009-08-18 Epix Delaware, Inc. Synthesis of thienopyridinone compounds and related intermediates
US7407966B2 (en) 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7598265B2 (en) * 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
WO2006081332A1 (en) 2005-01-25 2006-08-03 Epix Delaware, Inc. Substituted arylamine compounds and their use as 5-ht6 modulators
AU2006317689B2 (en) 2005-11-23 2013-07-25 Epix Delaware, Inc. S1P receptor modulating compounds and use thereof
AR061637A1 (es) 2006-06-26 2008-09-10 Epix Delaware Inc Composiciones y metodos de tratamiento de trastornos del snc
US20100184749A1 (en) 2006-10-12 2010-07-22 EPIX Delaware ,Inc. Benzothiadiazine compounds and their use
AR064245A1 (es) 2006-11-17 2009-03-25 Epix Delaware Inc Analogos de adenosina y su uso

Also Published As

Publication number Publication date
US20110195953A1 (en) 2011-08-11
ZA200804951B (en) 2009-04-29
AU2006315854A1 (en) 2007-05-24
CA2629312A1 (en) 2007-05-24
KR20080067001A (ko) 2008-07-17
WO2007058805A2 (en) 2007-05-24
EA200801302A1 (ru) 2009-02-27
TW200735868A (en) 2007-10-01
CN101340908A (zh) 2009-01-07
IL191168A0 (en) 2008-12-29
CR10062A (es) 2009-05-14
EP1959954A2 (en) 2008-08-27
MA30037B1 (fr) 2008-12-01
US20060234998A1 (en) 2006-10-19
CA2629312C (en) 2014-08-12
JP2009515877A (ja) 2009-04-16
BRPI0618493A2 (pt) 2011-08-30
NO20082679L (no) 2008-06-10
US7598265B2 (en) 2009-10-06
WO2007058805A3 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
AR057887A1 (es) Composiciones y metodos de tratamiento de trastornos del snc
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
AR078756A1 (es) Moduladores alostericos positivos (map)
AR065322A1 (es) 2-aminooxazolinas comoligandos de taar1
AR058885A1 (es) Compuestos de piperidina 3,5-sustituidos
AR072962A1 (es) Derivados de pirimidin-4-ona sustituidos
AR056838A1 (es) Derivados de 1,2,5-tiadiazol
AR055878A1 (es) Derivados de ciclopropanocarboxamida
AR063331A1 (es) Derivados de biaril eter urea y composiciones farmaceuticas
AR056320A1 (es) Derivados de cromano y cromeno, procesos de obtencion, composiciones farmaceuticas y usos de los mismos
ECSP045229A (es) Piridinonas sustituidas como moduladores de la p38 map quinasa
AR073348A1 (es) Inhibidores ciclicos de 11 beta-hidroxiesteroide deshidrogenasa 1
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
AR069165A1 (es) Derivados de 4-bencilamino-1-carboxacilpiperidina como inhibidores de cetp utiles para el tratamiento de hiperlipidemia
AR076460A1 (es) Antagonistas del receptor cxcr3
AR054783A1 (es) Derivados de pirrolo-quinolinas moduladores selectivos de receptores de androgeno
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR049346A1 (es) 3-amino-1-arilpropil-indoles como inhibidores de reabsorcion de monoaminas
AR059428A1 (es) Pirazoles para el tratamiento de enfermedades mediadas por la modulacion de los receptores de histamina h3 y una composicion farmaceutica que los comprende.
AR076008A1 (es) Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos.
UY30300A1 (es) Compuestos triarílicos y sus derivados
AR082111A1 (es) Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas
AR066103A1 (es) Derivados de triazolopiridin - carboxamidas, su preparacion y su aplicacion en terapeutica
CO6260069A2 (es) Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como moduladores de la leucotrieno a4 hidrolasa
AR057525A1 (es) Compuestos inhibidores selectivos de gsk3 y un proceso para su preparacion

Legal Events

Date Code Title Description
FA Abandonment or withdrawal